// App-Quantinova.ai

TP98 : SMTP-7, a Novel Thrombolytic With an Anti-inflammatory Potential, Improves Thrombotic Stroke With Little Bleeding Risk

Researchers

Presenter

  • Eriko Suzuki

Principal Investigators

  • Jie Zhuang

  • Keiji Hasumi

Medical Centers

  • Tokyo University of Agriculture and Technology, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Venous thrombosis

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Tranexamic acid

  • Caprilon

  • SMTP-7

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved